Peer Review History
| Original SubmissionSeptember 19, 2020 |
|---|
|
PONE-D-20-29592 Further characterization of the effect of the prototypical antidepressant imipramine on the microstructure of licking for sucrose PLOS ONE Dear Dr. D'Aquila, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Both reviewers recognized strengths of your study and the experimental design. However, there are a number of areas in which they felt additional analysis and commentary would help to understand the effects of imipramine. Please address each of those points in your revised manuscript. In addition, it is essential that all data (e.g. individual data points that underlie averages) are supplied or deposited online to comply with journal policy. Please submit your revised manuscript by Dec 24 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, James Edgar McCutcheon, Ph.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. We note that there is quite a bit of text overlap between your paper and the following papers from your author group: https://doi.org/10.1016/j.physbeh.2020.113032 https://doi.org/10.1016/j.ejphar.2020.173468 We would like to make you aware that copying extracts from previous publications, especially outside the methods section, word-for-word is unacceptable - whether the work is your own or another author group. In addition, the reproduction of text from published reports has implications for the copyright that may apply to the publications. Please revise the manuscript to rephrase the duplicated text and provide details as to how the current manuscript advances on previous work .We will carefully review your manuscript upon resubmission, so please ensure that your revision is thorough. Thank you for your attention to this matter! [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Overall, the experiment is very well designed and the analysis of the dose-dependant effect and the within session time course of imipramine’s effect brings important information about antidepressant effects on ingestive behaviour. I only have few comments: 1) The choice of either F-tests or Newman-Keuls post hoc tests after significant interactions was unclear both in the Methods and Results section. What informed these decisions? 2) The analysis of within session effect is especially interesting. I was wondering why the two first sessions have been included in this analysis (instead of only the 1st one or all of them)? 3) The analysis of the whole session number of licks per burst showed a clear significant increase during the first sessions in animals treated with 10 mg/kg imipramine. Even if it was not significant, a similar pattern can be noted with 5 and 20 mg/kg. I was wondering if the number of licks per burst was constant during the session or was evolving with the ingestion of sucrose under imipramine. 4) High doses of imipramine induced a decrease in body weight compared to vehicle injected rats but also compared to the rats’ original weight. Did the authors notice a decrease in food consumption beyond the sucrose ingestion procedure? 5) Animals receiving the highest dose of imipramine (20 mg/kg) seem to have an increased latency to lick associated with a general decrease of all the other licking parameters including the intra-burst lick rate. As suggested by the authors, this could reflect a potential locomotor effect. Even if it is beyond the scope of the present paper, I was wondering if the authors measured locomotor activity in imipramine-treated animals? 6) Colour code of Figures is sometimes a bit confusing with some symbols appearing white in some panels and black in others. This should be harmonized. 7) Authors should add a sentence about data availability and where data can be publicly found (either as Supplemental file or on a data repository) to comply with the journal's guideline. Reviewer #2: In this study, D’Aquila and Galistu examined the effects of repeated acute (1 hour prior) and delayed (24 hour prior) systemic administration of imipramine on sucrose intake and licking microstructure in rats. Analyses of licking patterns revealed that mid-high doses of this drug administered just before access to sucrose led to reductions in total licks over 30 minutes. This outcome was mainly accomplished via a reduction in the number of licking bursts and slower lick rate in response to imipramine, which is interpreted as an amplification of satiation processes (or reduction in reward processes). A similar intake pattern was observed if the drug was administered 24 hours prior to sucrose access at least at the highest dose, though this was less robust. The results are taken to suggest that imipramine’s acute effects are sufficient to reduce sucrose intake. This expands upon this group’s previous work, addressing a caveat from their earlier cited study whose design did not permit differentiation between the direct and indirect (e.g., CTA learning) effects of the drug on sucrose consumption. Although the study expands upon the prior work in an incremental fashion, there are several outstanding interpretational and technical concerns. These are listed below. First, the overall design and rationale for the design are somewhat difficult to follow as presented. A timeline would be helpful in this regard. For example, the rats were acclimated to the sucrose in the lickometers, but for how long, how many sessions, with food or water deprivation? During the interposed non-test sessions, were the rats provided sucrose as usual? If the primary outcome of interest here was burst number and total intake, it’s unclear why the groups were matched on burst size. The rationale for selecting a 400 ms pause criterion is not clear. Previous work in rats found that a >1 second pause criterion captured both short and long breaks between active licking bursts. Perhaps this criterion would decrease some of the noise in the burst data. Spector AC, Klumpp PA, Kaplan JM. Analytical issues in the evaluation of food deprivation and sucrose concentration effects on the microstructure of licking behavior in the rat. Behav Neurosci. 1998 Jun;112(3):678-94. With respect to the prior study, upon which this one is based, if CTA was one possible mechanism, then this would be expected to appear as an increase in burst number, with a corresponding decrease in burst size, as rats would less readily consume the substance. This would reflect a devaluation of the orosensory properties of the sucrose. Moreover, one would expect, based on the previous literature, that the initial lick rate (or first burst size), which are rendered by the orosensory input of the stimulus, prior to the onset of any postingestive effects, would be reduced in the group that received the drug from the first exposure to the last. This too would reflect a learned or indirect effect of the drug or a primary effect on reward versus satiation. Familiarization with sucrose prior to testing with the drug would be expected to attenuate any learning about the stimulus here. For this reason, it would be helpful to clarify the nature of the acclimation phase and acknowledge that as a caveat in the present design. Analyses of the interlick interval distributions would provide a more reliable check on motor impairments produced by the drug. Nevertheless, there are potential indications in the data presented here for unconditioned and conditioned/repeated effects of the drugs. The effects of the drug appear weaker on the initial session (day 1) relative to subsequent sessions (including in latency to initiate licking). There also appears to be substantial weight loss from start to finish in the high dose groups. For this reason, it might be worthwhile to analyze /discuss the initial session (day 1) as compared to the subsequent 1-hour prior sessions. Do total licks and licking patterns return to normal in between the tests (the “off” days)? Such data could be informative with respect to teasing apart the effects modulated by drug state contexts/conditioning and unconditioned effects of the drug. Given the strong conclusions offered in lines 262-266 and in the final paragraph of the discussion that reduced sugar consumption “does not depend on post-session administration” and is related to the acute effect of the drug on board during testing, these issues need to be resolved more fully. In general, the repeated drug exposure nature design and order effects are not sufficiently considered. A separate experiment specifically assessing whether these doses condition avoidance of a novel flavor would help resolve these issues. There is certainly a trend for higher doses of imipramine to reduce burst number and intra-burst lick rate in the 24-hour post injection condition- in some cases this reaches significance. Therefore, a fuller discussion of potential long term effects of the drug are warranted, while keeping in mind that these rats had extensive exposure to this drug prior to the 24 hour post-injection phase. The initial phase (1 hr) should be analyzed separately from the later phase (interposed with 24 hr) sessions. Discussion of the relationship between burst size and number across sessions 1 and 5 in lines 296-301 is unclear, as only burst numbers are plotted. The argument appears to be that reduced burst number and increase burst size typically results in a similar total licks outcome, not a reduced lick outcome as seen in this study. Parallel plots of burst size (or licks/bin) across these bins would perhaps help make the point clearer. The argument in Discussion lines 319-324 is not entirely convincing, given burst size is quite variable, and perhaps increased early on in the 10 mg dose condition. Moreover, it would be worth considering whether this “early” increase in burst size in the 10 mg condition that disappears after the first of the 24 hour post-injection sessions is related to those treatments or just a function of the repeated exposure. Decreased burst number is referred to as satiety throughout (e.g., line 310), when this perhaps more accurately tracks satiation in these short term sessions. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Fabien Naneix Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-29592R1 Further characterization of the effect of the prototypical antidepressant imipramine on the microstructure of licking for sucrose PLOS ONE Dear Dr. D'Aquila, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Both reviewers recognized that substantial improvement had been made to the paper since the first submission. However, before acceptance once reviewer has still requested some additional details and presentation of a little more of the within-session data. Please attend to their comments before re-submitting. Please submit your revised manuscript by Feb 06 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, James Edgar McCutcheon, Ph.D. Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: The paper is greatly improved by reframing of it in terms of examining the “immediate” effects of the imipramine on sucrose licking patterns in the absence of interposed post-session administrations, as opposed to invoking some examination of learning or memory. In general, the discussion is a lot more cautious about mechanism, which is appropriate given the design and data. I still have a couple of outstanding concerns. Perhaps the authors could add some indication of which sessions are included in part 1 and 2 in the table. But, in general, the table helps clarify the protocol. I would like to see more of the within session data (plotted across time). Per my previous review, I thought it would be important to examine burst size in addition to be able to interpret the burst number data across the session. The authors now present the first 3 min burst size in the supporting information, but not beyond that. The authors appear to favor the interpretation that imipramine reduces behavioral motivation or increases satiation. But for the 10 mg dose (and maybe the 5), the data could just as easily be interpreted as increase in “hedonic value” based on the framework provided by the authors in the introduction. In fact, the first 3 minute burst data, which overlap well with the overall session burst data, in Fig S1, would seem to indicate that burst size is increased prior to satiation signals coming online (i.e., in the early part of the session). Perhaps looking at dynamic changes in lick rate (or burst size) in the 3 min bins across the entire session would clarify. The burst size does not appear to be reduced until the second phase of the experiment. This may be a limitation of interpreting burst size as a function of reward and burst number as a function of motivation. Of course, it is impossible to know whether this is simply due to an accumulation of drug or something about the pre and post injection procedure. I suppose, at the very least, if the drug at these doses was increasing the rewarding value of sucrose, it did not drive overconsumption (intake was pretty stable across the days). Line 45-46 is a little unclear. Burst number cannot be separated from orosensory cues in this design. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Dr. Fabien Naneix Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Further characterization of the effect of the prototypical antidepressant imipramine on the microstructure of licking for sucrose PONE-D-20-29592R2 Dear Dr. D'Aquila, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, James Edgar McCutcheon, Ph.D. Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-20-29592R2 Further characterization of the effect of the prototypical antidepressant imipramine on the microstructure of licking for sucrose Dear Dr. D'Aquila: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. James Edgar McCutcheon Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .